Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • ottoblau
    Junior Member
    • Sep 2010
    • 2

    #1

    Class action suit against Illumina?

    Illumina repeatedly has problems to deliver chemistry for sequencers. As long as chemistry cannot be delivered, sequencers cannot be used. If you have a service contract for a sequencer this means that you pay for something useless during these weeks or months!

    This means that the entire community of Illumina sequencer users is affected and pays service contracts for temporarily non-usable instruments. Since service contracts go by ten-thousands of $ or € per year, the big number of affected labs together loose a lot of money.

    Does anybody know a lawyer who would be interested to see if we could recover some of the service contract money?
  • pmiguel
    Senior Member
    • Aug 2008
    • 2328

    #2
    How many Illumina sequencers do you have ottoblau? (Just curious.)

    Actually, Illumina seems par for the course reagent back-order-wise to me. (We also have a SOLiD and a 454). But I was somewhat irritated to see reports of high Illumina officials proclaiming to the media that their v3 chemistry basically created a sequence glut and that's why their profits were not what they were hoping last quarter.

    Even though the delays for getting run chemistry have not been too bad (usually a week or two at most), it makes me wonder if Illumina bothers to account for the loss in sales that having their instruments idle due to reagent shortages represents?

    I get the impression that a school of supply chain management that strongly favors low standing inventories has gained control of most of the major instrument reagent companies because it looks good on paper.

    --
    Phillip

    Comment

    • ECO
      --Site Admin--
      • Oct 2007
      • 1360

      #3
      In our experience, the louder you yell, the shorter the backorder time becomes...they clearly prioritize by who's the angriest.

      Comment

      • ottoblau
        Junior Member
        • Sep 2010
        • 2

        #4
        Class Action Suit Illumina

        You both are right, Philip and ECO, you have to yell at Illumina and the others are not better!
        We pay over 40,000$ per year for a service contract, i.e. over 100$ per day. No chemistry, no sequencer. Class action should bring a good amount of money together and should be interesting for a lawyer?
        Since you asked, Philip, we have one sequencer and this seems to be part of the problem. Small customers are not interesting at all for Illumina.

        Comment

        Latest Articles

        Collapse

        • SEQadmin2
          Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
          by SEQadmin2


          Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

          The systematic characterization of the human proteome has
          ...
          07-20-2026, 11:48 AM
        • SEQadmin2
          Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
          by SEQadmin2



          Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
          ...
          07-09-2026, 11:10 AM
        • SEQadmin2
          Cancer Drug Resistance: The Lingering Barrier to Rising Survival
          by SEQadmin2



          Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

          There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
          07-08-2026, 05:17 AM

        ad_right_rmr

        Collapse

        News

        Collapse

        Topics Statistics Last Post
        Started by SEQadmin2, Today, 02:55 AM
        0 responses
        4 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 07-24-2026, 12:17 PM
        0 responses
        10 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 07-23-2026, 11:41 AM
        0 responses
        11 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 07-20-2026, 11:10 AM
        0 responses
        23 views
        0 reactions
        Last Post SEQadmin2  
        Working...